Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Georg, Hopfinger"'
Autor:
Nina Worel, Katharina Grabmeier-Pfistershammer, Bernhard Kratzer, Martina Schlager, Andreas Tanzmann, Arno Rottal, Ulrike Körmöczi, Edit Porpaczy, Philipp B. Staber, Cathrin Skrabs, Harald Herkner, Venugopal Gudipati, Johannes B. Huppa, Benjamin Salzer, Manfred Lehner, Nora Saxenhuber, Eleonora Friedberg, Philipp Wohlfarth, Georg Hopfinger, Werner Rabitsch, Ingrid Simonitsch-Klupp, Ulrich Jäger, Winfried F. Pickl
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
BackgroundChimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this het
Externí odkaz:
https://doaj.org/article/b9b90c9752894772a6c70577e2f23cde
Autor:
Johanna Schreiber, Alexander Pichler, Christoph Kornauth, Hannes Kaufmann, Philipp B. Staber, Georg Hopfinger
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/c8c8a58b6ca647f7b09b7cc8506f6cf1
Publikováno v:
memo - Magazine of European Medical Oncology. 16:79-90
SummaryChimeric antigen receptor (CAR) T cell therapies offer a promising new therapeutic option for treating B cell malignancies, for instance relapsed or refractory diffuse large B cell lymphoma (DLBCL). However, patient access to this type of cell
Autor:
Christoph Kornauth, Charles Herbaux, Bernd Boidol, Chantal Guillemette, Patrick Caron, Marius E. Mayerhöfer, Stéphanie Poulain, Olivier Tournilhac, Tea Pemovska, Stephen J.F. Chong, Emiel van der Kouwe, Lukas Kazianka, Georg Hopfinger, Daniel Heintel, Roland Jäger, Markus Raderer, Ulrich Jäger, Ingrid Simonitsch-Klupp, Wolfgang R. Sperr, Stefan Kubicek, Matthew S. Davids, Philipp B. Staber
Publikováno v:
Haematologica, Vol 106, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/70f236cee2eb4fb78d1d6993e60eed17
Autor:
Philipp B. Staber, Berend Snijder, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Niklas Zojer, Christoph C. Zielinski, Dominik Wolf, Cora Waldstein, Stefan Vogt, Katrina Vanura, Emiel van der Kouwe, Peter Valent, Renate Thalhammer, Ismet Srndic, Wolfgang R. Sperr, Cathrin Skrabs, Christian Sillaber, Edgar Selzer, Ilse Schwarzinger, Ann-Sofie Schmolke, Ana-Iris Schiefer, Julius Salamon, Reinhard Ruckser, Robin Ristl, Markus Raderer, Gerald W. Prager, Edit Porpaczy, Alexander Pichler, Michael Panny, Leopold Öhler, Katharina Ocko, Thomas Noesslinger, Peter Neumeister, Leonhard Müllauer, Katsuhiro Miura, Olaf Merkel, Elisabeth Menschel, Marius E. Mayerhoefer, Simone Lubowitzki, Trang Le, Stefan Kubicek, Gerhard Krajnik, Nikolaus Krall, Barbara Kiesewetter, Lukas Kenner, Lukas Kazianka, Ulrich Jaeger, Georg Hopfinger, Mir Alireza Hoda, Daniel Heintel, Tim Heinemann, Alexander W. Hauswirth, Bernd Lorenz Hartmann, Marcus Hacker, Wolfgang Gstöttner, Hildegard T. Greinix, Klaus Geissler, Alexander Gaiger, Maurizio Forte, Verena Felsleitner-Hauer, Ruth Exner, Harald Esterbauer, Martin Erl, Ruth Eichner, Sandra Eder, Michael Bergmann, Günther Bayer, Gregory I. Vladimer, Tea Pemovska, Christoph Kornauth
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9887042c05486a909c745cd96689d6c
https://doi.org/10.1158/2159-8290.c.6549464.v1
https://doi.org/10.1158/2159-8290.c.6549464.v1
Publikováno v:
HemaSphere, Vol 3, Iss 2 (2019)
Abstract. Patients with non-Hodgkin lymphomas (NHLs) resistant to standard therapies have a dismal prognosis. The outcome is even poorer in patients relapsing after autologous stem cell transplantation. Most of these patients do not qualify for an al
Externí odkaz:
https://doaj.org/article/b0ab9885287b4a56b5495c767a23dd05
Autor:
Leopold Öhler, Philipp B. Staber, Julius Salamon, Edit Porpaczy, Gerhard Krajnik, Gregory I. Vladimer, Harald Esterbauer, Ulrich Jaeger, Christian Sillaber, Gerald W. Prager, Katrina Vanura, Stefan Kubicek, Peter Valent, Michael Panny, Alexander W. Hauswirth, Edgar Selzer, Verena Felsleitner-Hauer, Emiel van der Kouwe, Nikolaus Krall, Marius E. Mayerhoefer, Bernd Lorenz Hartmann, Alexander Gaiger, Sandra Eder, Klaus Geissler, Mir Alireza Hoda, Dominik Wolf, Simone Lubowitzki, Peter Neumeister, Barbara Kiesewetter, Ruth Exner, Giulio Superti-Furga, Thomas Noesslinger, Elisabeth Menschel, Katsuhiro Miura, Wolfgang Gstöttner, Reinhard Ruckser, Ingrid Simonitsch-Klupp, Hildegard Greinix, Ana-Iris Schiefer, Ann-Sofie Schmolke, Cora Waldstein, Georg Hopfinger, Christoph C. Zielinski, Wolfgang R. Sperr, Marcus Hacker, Trang Le, Robin Ristl, Christoph Kornauth, Lukas Kazianka, Tea Pemovska, Günther Bayer, Cathrin Skrabs, Markus Raderer, Ruth Eichner, Alexander Pichler, Lukas Kenner, Maurizio Forte, Renate Thalhammer, Stefan Vogt, Leonhard Müllauer, Katharina Ocko, Niklas Zojer, Berend Snijder, Ilse Schwarzinger, Olaf Merkel, Martin Erl, Daniel Heintel, Michael Bergmann, Tim Heinemann, Ismet Srndic
Publikováno v:
Cancer Discovery, 12 (2)
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Autor:
Michaela Kotrova, H J M Göx, Jan Dürig, Dimitrios Mougiakakos, J Makalowski, Prerana Wagle, T Neumann, Till Braun, Sebastian Oberbeck, Alexandra Schrader, Hinrich Abken, Monika Brüggemann, Marco Herling, Richard Moriggl, Martin Thelen, A Kondo Ados, Petra Mayer, Janine Altmüller, Tero Aittokallio, Sylvia Hartmann, Sebastian Newrzela, Linus Wahnschaffe, Thorsten Persigehl, Giuliano Crispatzu, Natali Pflug, Georg Hopfinger, Michael Hallek, Kathrin Warner, Alyssa Bouska, L. Varghese, M. L. Hansmann, Javeed Iqbal, J. von Jan, S. Pützer, Ingo Roeder, T A Müller, Gunter Rappl, M von Bergwelt-Baildon, S. Stilgenbauer, D Jungherz, Hans H. Diebner, Aleksandr Ianevski, Nicole Riet, Markus Chmielewski, Hans A. Schlößer
Publikováno v:
Blood. 136:2786-2802
T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are insufficiently characterized. Constitutive activation of the T-cell leukemia 1A (TCL1A) oncogen
Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease
Autor:
Thomas Krausgruber, Merima Herac, Georg Hopfinger, Nadine Bayer, Philipp Wohlfarth, Margit Mitterbauer, Georg Stary, Peter Kalhs, Lisa Kleissl, Christoph Krall, Bärbel Reininger, Christoph Bock, Werner Rabitsch, J. Strobl, Ram Vinay Pandey
Publikováno v:
Journal of Investigative Dermatology. 140:2188-2198
Graft-versus-host disease (GVHD) is the leading cause of mortality after hematopoietic stem cell transplantation and primarily affects barrier organs such as the skin. One-third of cases are refractory to steroid treatment resulting in poor outcomes
Autor:
Bertold Emmerich, Werner Freier, Martin Bentz, Hartmut Döhner, Lothar Müller, Kirsten Fischer, Manuela Hoechstetter, Dirk Winkler, Sandra Robrecht, Georg Hopfinger, Carmen D. Herling, Ilona Blau, Frank Hartmann, Georg Jacobs, Barbara Eichhorst, Ulrich Jäger, Jasmin Bahlo, Ursula Vehling-Kaiser, Maria Elisabeth Goebeler, Michael J. Eckart, Clemens M. Wendtner, Andreas Bühler, Michael Starck, Wolfgang Abenhardt, Hans Jürgen Hurtz, Harald Fuss, Stephan Stilgenbauer, Raymonde Busch, Michael Hallek
Publikováno v:
Leukemia. 34:1038-1051
The heterogeneity of early stage CLL challenges prognostication, and refinement of prognostic indices for risk-adapted management in this population is essential. The aim of the multicenter, prospective CLL1 trial was to explore a novel prognostic mo